Repligen Corp

Research Repligen Corp (RGEN) on Bullrun: valuation model: 61.1% overvalued, market cap USD 7.73B, P/E 150.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRGEN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryMedical Instruments & Supplies
• CurrencyUSD
• Valuation signal61.1% overvalued
• Market capUSD 7.73B
• P/E150.8
• Financial periodFY2025
• RevenueUSD 738.26M
• Revenue growth16.4%
• Net incomeUSD 48.89M
• Free cash flowUSD 93.90M
• Gross margin52.3%

Valuation Snapshot

Bullrun's latest valuation model marks Repligen Corp as 61.1% overvalued; latest market cap is USD 7.73B; P/E is 150.8.

About Repligen Corp

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer;

Frequently asked questions

Is Repligen Corp overvalued or undervalued?

Bullrun's valuation model currently marks Repligen Corp as 61.1% overvalued.

What is Repligen Corp's market cap?

Repligen Corp's market capitalization is USD 7.73B.

What is Repligen Corp's P/E ratio?

Repligen Corp's price-to-earnings (P/E) ratio is 150.8.

What does Repligen Corp do?

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.